XORTX Therapeutics Inc. (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announced that its Pharmacokinetics Bridging Study – XRX-OXY-101 – Part 2 showed a significant increase in oral bioavailability of XORTX’s proprietary oxypurinol formulation provided with...
Insider selling or buying cannot be the sole indicator for investing in a stock, but it would be wise to make a note of the buying and selling activities to gauge a company’s prospects or the lack thereof. While insiders buying or selling the Company’s...
Clinical-Stage companies offer an exciting investment opportunity with massive upside potential. Most of these companies bring new and highly differentiated approaches, advanced scientific knowledge and a zeal for innovation to the table. However, clinical trials are fraught with risk and uncertainty. Even the slightest setback can...
Indie Semiconductor, Inc. (NASDAQ: INDI), a Company offering automotive semiconductors and software solutions for the automotive industry announced the completion of its business combination with Thunder Bridge Acquisition II, Ltd, a special purpose acquisition company (SPAC) on June 9, 2011. The transaction resulted in gross...
Entera Bio Ltd. (NASDAQ: ENTX), a clinical-stage biotechnology company, developing leading-edge orally delivered large molecule therapeutics, announced pivotal 6-month bone mineral density (BMD) results from the Phase 2 clinical trial of EB613, intended for the treatment of osteoporosis. EB613, the Company’s lead candidate for the...
VivoPower International PLC (NASDAQ: VVPR), a Company striving to create sustainable energy solutions, announced that the Company has entered into a binding letter of Intent (“LOI”) for the electrification of Toyota’s Landcruiser vehicles, through its wholly-owned subsidiary Tembo e-LV B.V. The collaboration with Toyota Motor...
Alzheimer’s is the sixth leading cause of death in the U.S, a disease that causes irreversible degeneration of the brain cells and affects a person’s cognitive and behavioral abilities such as impaired judgment, deteriorating memory and personality changes with the gradual loss of motor abilities...
Scholar Rock Holding (NASDAQ: SRRK), a clinical-stage biopharmaceutical Company, announced the grant of a Fast-Track Designation for apitegromab, a selective inhibitor of myostatin activation, intended for the treatment of Spinal Muscular Atrophy (SMA) by the U.S. Food and Drug Administration (FDA). The candidate has previously...
Second Sight Medical Products, Inc. (NASDAQ: EYES), a developer of leading-edge implantable visual prosthetics, announced the results from a two-year study evaluating the feasibility of the Orion Visual Cortical Prosthesis (Orion). The Orion® Visual Cortical Prosthesis System is a next-generation device that provides artificial vision to...
Biotech Companies continue to show resurgence even in these challenging times, with more and more companies persevering with bringing their clinical candidates to fruition. While Vaccine development and therapeutics to combat the COVID-19 pandemic are at the forefront of development activities in the biotech sector,...
